A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors

Molecular Cell

Volumn 62, Issue 2, 2016, Pages 307-313

  Ruiz, Sergio ^a   Mayor Ruiz, Cristina ^a   Lafarga, Vanesa ^a   Murga, Matilde ^a   Vega Sendino, Maria ^a   Ortega, Sagrario ^a   Fernandez Capetillo, Oscar ^a,b  

^a Centro Nacional de Investigations Oncológicas   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATR KINASE INHIBITOR; ATR PROTEIN; CDC25A PROTEIN; COMPLEMENTARY DNA; DOUBLE STRANDED DNA; HISTONE H2AX; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN, MOUSE; CDC25A PROTEIN, MOUSE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; WEE1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL SELECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRISPR CAS SYSTEM; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; EMBRYO; EMBRYONIC STEM CELL; ENZYME INHIBITION; GENE INTERACTION; GENETIC ASSOCIATION; HETEROZYGOSITY; MITOSIS; MOUSE; NONHUMAN; PHARMACOGENETICS; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CDC25 PHOSPHATASES; CELL CYCLE PROTEINS; CELL LINE; CRISPR-CAS SYSTEMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EMBRYONIC STEM CELLS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MITOSIS; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84962777892     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2016.03.006     Document Type: Article

References (35)

1. Beard C., Hochedlinger K., Plath K., Wutz A., Jaenisch R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 2006, 44:23-28.
2. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
3. Buisson R., Boisvert J.L., Benes C.H., Zou L. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Mol. Cell 2015, 59:1011-1024.
4. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9:616-627.
5. Collart M.A., Panasenko O.O. The Ccr4-not complex. Gene 2012, 492:42-53.
6. Derenzini E., Agostinelli C., Imbrogno E., Iacobucci I., Casadei B., Brighenti E., Righi S., Fuligni F., Ghelli Luserna Di Rorà A., Ferrari A., et al. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 2015, 6:6553-6569.
7. Eykelenboom J.K., Harte E.C., Canavan L., Pastor-Peidro A., Calvo-Asensio I., Llorens-Agost M., Lowndes N.F. ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. Cell Rep. 2013, 5:1095-1107.
8. Falck J., Mailand N., Syljuåsen R.G., Bartek J., Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842-847.
9. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
10. Flynn R.L., Cox K.E., Jeitany M., Wakimoto H., Bryll A.R., Ganem N.J., Bersani F., Pineda J.R., Suvà M.L., Benes C.H., et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015, 347:273-277.
11. Foote K.M., Blades K., Cronin A., Fillery S., Guichard S.S., Hassall L., Hickson I., Jacq X., Jewsbury P.J., McGuire T.M., et al. Discovery of 4-4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. 2013, 56:2125-2138.
12. Galaktionov K., Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991, 67:1181-1194.
13. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
14. Koike-Yusa H., Li Y., Tan E.P., Velasco-Herrera Mdel.C., Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 2014, 32:267-273.
15. Kwok M., Davies N., Agathanggelou A., Smith E., Petermann E., Yates E., Brown J., Lau A., Stankovic T. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet 2015, 385(Suppl 1):S58.
16. Lecona E., Fernández-Capetillo O. Replication stress and cancer: it takes two to tango. Exp. Cell Res. 2014, 329:26-34.
17. López-Contreras A.J., Fernandez-Capetillo O. The ATR barrier to replication-born DNA damage. DNA Repair (Amst.) 2010, 9:1249-1255.
18. Lopez-Contreras A.J., Specks J., Barlow J.H., Ambrogio C., Desler C., Vikingsson S., Rodrigo-Perez S., Green H., Rasmussen L.J., Murga M., et al. Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes Dev. 2015, 29:690-695.
19. Mailand N., Falck J., Lukas C., Syljuâsen R.G., Welcker M., Bartek J., Lukas J. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288:1425-1429.
20. Mankouri H.W., Huttner D., Hickson I.D. How unfinished business from S-phase affects mitosis and beyond. EMBO J. 2013, 32:2661-2671.
21. Minocherhomji S., Ying S., Bjerregaard V.A., Bursomanno S., Aleliunaite A., Wu W., Mankouri H.W., Shen H., Liu Y., Hickson I.D. Replication stress activates DNA repair synthesis in mitosis. Nature 2015, 528:286-290.
22. Murga M., Campaner S., Lopez-Contreras A.J., Toledo L.I., Soria R., Montaña M.F., D'Artista L., Schleker T., Guerra C., Garcia E., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 2011, 18:1331-1335.
23. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
24. Pfister S.X., Markkanen E., Jiang Y., Sarkar S., Woodcock M., Orlando G., Mavrommati I., Pai C.C., Zalmas L.P., Drobnitzky N., et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell 2015, 28:557-568.
25. Prevo R., Fokas E., Reaper P.M., Charlton P.A., Pollard J.R., McKenna W.G., Muschel R.J., Brunner T.B. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 2012, 13:1072-1081.
26. Ray D., Kiyokawa H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008, 68:1251-1253.
27. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., Golec J.M., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
28. Russell P., Nurse P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986, 45:145-153.
29. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., Elledge S.J. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997, 277:1497-1501.
30. Santos M.A., Faryabi R.B., Ergen A.V., Day A.M., Malhowski A., Canela A., Onozawa M., Lee J.E., Callen E., Gutierrez-Martinez P., et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature 2014, 514:107-111.
31. Sarmento L.M., Póvoa V., Nascimento R., Real G., Antunes I., Martins L.R., Moita C., Alves P.M., Abecasis M., Moita L.F., et al. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. Oncogene 2015, 34:2978-2990.
32. Schoppy D.W., Ragland R.L., Gilad O., Shastri N., Peters A.A., Murga M., Fernandez-Capetillo O., Diehl J.A., Brown E.J. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 2012, 122:241-252.
33. Toledo L.I., Murga M., Zur R., Soria R., Rodriguez A., Martinez S., Oyarzabal J., Pastor J., Bischoff J.R., Fernandez-Capetillo O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 2011, 18:721-727.
34. Toledo L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., Bekker-Jensen S., Mailand N., Bartek J., Lukas J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155:1088-1103.
35. Vendetti F.P., Lau A., Schamus S., Conrads T.P., O'Connor M.J., Bakkenist C.J. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 2015, 6:44289-44305.